Quest Diagnostics/$DGX
1D1W1MYTD1Y5YMAX
Capital at risk
About Quest Diagnostics
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
- Ticker
- $DGX
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 51,500
- Headquarters
- Secaucus, United States
- Website
- www.questdiagnostics.com
DGX Metrics
BasicAdvanced
$26B
24.54
$9.42
0.55
$3.32
1.49%
Price and volume
Market cap
$26B
Beta
0.55
52-week high
$248.84
52-week low
$171.18
Average daily volume
1.1M
Dividend rate
$3.32
Financial strength
Current ratio
1.591
Quick ratio
1.282
Long term debt to equity
0.787
Total debt to equity
0.808
Dividend payout ratio (TTM)
34.18%
Interest coverage (TTM)
6.27%
Profitability
EBITDA (TTM)
2,272
Gross margin (TTM)
33.19%
Net profit margin (TTM)
9.19%
Operating margin (TTM)
14.58%
Effective tax rate (TTM)
22.33%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
6.43%
Return on equity (TTM)
14.60%
Valuation
Price to earnings (TTM)
24.54
Price to revenue (TTM)
2.199
Price to book
3.38
Price to tangible book (TTM)
-7.78
Price to free cash flow (TTM)
18.844
Free cash flow yield (TTM)
5.31%
Free cash flow per share (TTM)
12.264
Dividend yield (TTM)
1.44%
Forward dividend yield
1.49%
Growth
Revenue change (TTM)
9.87%
Earnings per share change (TTM)
12.83%
3-year revenue growth (CAGR)
6.81%
10-year revenue growth (CAGR)
4.42%
3-year earnings per share growth (CAGR)
11.02%
10-year earnings per share growth (CAGR)
5.09%
3-year dividend per share growth (CAGR)
6.61%
10-year dividend per share growth (CAGR)
7.85%
What the Analysts think about DGX
Analyst ratings (Buy, Hold, Sell) for Quest Diagnostics stock.
Analyst projections of the future price of Quest Diagnostics stock.
Bulls say / Bears say
Quest beat second-quarter expectations, with revenue up 10.2% and adjusted EPS up 19.1%. It raised its 2026 revenue outlook to $11.95bn-$12.05bn and adjusted EPS outlook to $11.05-$11.25, showing strong demand across physician, hospital and consumer channels. (Reuters, Quest Diagnostics)
Consumer health is becoming a meaningful growth engine. Quest said its consumer business was a $250m operation at the end of 2025 and expected it to grow by at least 30% in 2026, helped by QuestHealth.com and partnerships with digital wellness brands. (Markets Daily, Quest Diagnostics)
Quest is widening its specialised-testing opportunity. It plans to launch a Roche pTau217 Alzheimer's test service in the fourth quarter and is integrating oncology testing into OncoEMR, which could make its tests easier to order across 4,700 clinicians in the Flatiron network. (Quest Diagnostics, Quest Diagnostics)
Potential PAMA changes could cut Medicare laboratory rates by up to 15% in 2027. Evercore estimates the effect could reduce Quest's adjusted operating income by roughly $90m-$100m, making the final CMS decision a material earnings risk. (Investing.com, Markets Daily)
Profit is not yet converting growth cleanly into margins. Second-quarter adjusted operating margin fell 40 basis points to 16.5%, as lower-margin Corewell and Fresenius work, Project Nova and higher costs weighed on results; heavier Nova spending and fuel costs are expected in the second half. (Yahoo Finance, Quest Diagnostics)
Leverage reduces financial flexibility. At 30 June, Quest had $5.63bn of long-term debt against $626m of cash, while first-half interest expense was $126m; further spending on acquisitions, automation and Project Nova could limit room for error. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
DGX Financial Performance
Revenues and expenses
DGX Earnings Performance
Company profitability
Upcoming events
DGX News
AllArticlesVideos
Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
MarketBeat2 weeks ago
Quest Diagnostics typically performs between 30 and 40 cyclospora tests a day. Now it's processing more than 1,500.
WSJ2 months ago
Quest Diagnostics CEO: AI is helping patients understand their doctors
Fox Business2 months ago
Funds containing DGX
AllEURUSDGBP
Fund name | Fund size | $DGX weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.56% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.43% |
iShares Edge MSCI World Minimum Volatility$MVOL | $2.6B | 0.38% |
iShares Edge MSCI World Minimum Volatility€IQQ0 | €2.3B | 0.38% |
iShares Edge MSCI World Minimum Volatility£MINV | £1.9B | 0.38% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.